Prevalence and pathogenesis of diabetes mellitus in HIV-1 infection treated with combined antiretroviral therapy

J Acquir Immune Defic Syndr. 2009 Apr 15;50(5):499-505. doi: 10.1097/QAI.0b013e31819c291b.

Abstract

Combined antiretroviral therapy (cART) in the treatment of HIV-1 infection confers significant survival benefit and, by immunoreconstitution, has altered the natural history of this life-threatening disease. Metabolic complications of cART include hyperlipidemia, insulin resistance, and lipodystrophy, with resultant increases in risk for type 2 diabetes and cardiovascular disease. These diseases will present new challenges in the management of HIV infection. This article reviews the prevalence of diabetes mellitus and its antecedents in HIV-infected patients treated with cART. It also reviews the current understanding of mechanisms involved in the pathogenesis of type 2 diabetes in cART considering insulin resistance and insulin secretion, both requisites for the development of type 2 diabetes mellitus.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Anti-HIV Agents / administration & dosage
  • Anti-HIV Agents / therapeutic use*
  • Diabetes Mellitus / epidemiology*
  • Diabetes Mellitus / etiology*
  • Drug Therapy, Combination
  • HIV Infections / complications*
  • HIV Infections / drug therapy*
  • HIV Infections / epidemiology
  • Humans
  • Prevalence

Substances

  • Anti-HIV Agents